vs
AMTECH SYSTEMS INC（ASYS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是AMTECH SYSTEMS INC的1.6倍（$30.3M vs $19.0M），AMTECH SYSTEMS INC净利率更高（0.6% vs -221.3%，领先221.9%），REGENXBIO Inc.同比增速更快（43.0% vs -22.2%），AMTECH SYSTEMS INC自由现金流更多（$3.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -13.6%）
Amtech Systems Inc是一家全球领先的热处理及自动化设备制造商，核心产品面向半导体、光伏太阳能、LED生产领域，覆盖焊接、扩散、沉积等工艺设备，主要市场包括北美、东亚及西欧，服务电子元器件、清洁能源制造领域的头部客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ASYS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$19.0M
营收增速更快
RGNX
高出65.2%
-22.2%
净利率更高
ASYS
高出221.9%
-221.3%
自由现金流更多
ASYS
多$56.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-13.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.0M | $30.3M |
| 净利润 | $108.0K | $-67.1M |
| 毛利率 | 44.8% | — |
| 营业利润率 | 4.1% | -190.0% |
| 净利率 | 0.6% | -221.3% |
| 营收同比 | -22.2% | 43.0% |
| 净利润同比 | -65.4% | -31.2% |
| 每股收益（稀释后） | $0.01 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASYSRGNX
| Q4 25 | $19.0M | $30.3M | ||
| Q3 25 | $19.8M | $29.7M | ||
| Q2 25 | $19.6M | $21.4M | ||
| Q1 25 | $15.6M | $89.0M | ||
| Q4 24 | $24.4M | $21.2M | ||
| Q3 24 | $24.1M | $24.2M | ||
| Q2 24 | $26.7M | $22.3M | ||
| Q1 24 | $25.4M | $15.6M |
净利润ASYSRGNX
| Q4 25 | $108.0K | $-67.1M | ||
| Q3 25 | $1.1M | $-61.9M | ||
| Q2 25 | $106.0K | $-70.9M | ||
| Q1 25 | $-31.8M | $6.1M | ||
| Q4 24 | $312.0K | $-51.2M | ||
| Q3 24 | $-536.0K | $-59.6M | ||
| Q2 24 | $438.0K | $-53.0M | ||
| Q1 24 | $970.0K | $-63.3M |
毛利率ASYSRGNX
| Q4 25 | 44.8% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | -2.1% | — | ||
| Q4 24 | 38.4% | 70.2% | ||
| Q3 24 | 40.7% | 48.8% | ||
| Q2 24 | 36.5% | 52.5% | ||
| Q1 24 | 33.2% | 72.6% |
营业利润率ASYSRGNX
| Q4 25 | 4.1% | -190.0% | ||
| Q3 25 | 9.3% | -176.3% | ||
| Q2 25 | 4.7% | -296.3% | ||
| Q1 25 | -202.7% | 13.6% | ||
| Q4 24 | 1.4% | -242.1% | ||
| Q3 24 | 0.1% | -256.6% | ||
| Q2 24 | 3.1% | -251.3% | ||
| Q1 24 | 5.4% | -408.8% |
净利率ASYSRGNX
| Q4 25 | 0.6% | -221.3% | ||
| Q3 25 | 5.4% | -208.3% | ||
| Q2 25 | 0.5% | -331.8% | ||
| Q1 25 | -204.2% | 6.8% | ||
| Q4 24 | 1.3% | -241.3% | ||
| Q3 24 | -2.2% | -246.3% | ||
| Q2 24 | 1.6% | -237.7% | ||
| Q1 24 | 3.8% | -405.4% |
每股收益（稀释后）ASYSRGNX
| Q4 25 | $0.01 | $-1.30 | ||
| Q3 25 | $0.08 | $-1.20 | ||
| Q2 25 | $0.01 | $-1.38 | ||
| Q1 25 | $-2.23 | $0.12 | ||
| Q4 24 | $0.02 | $-0.99 | ||
| Q3 24 | $-0.04 | $-1.17 | ||
| Q2 24 | $0.03 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.1M | $230.1M |
| 总债务越低越好 | $162.0K | — |
| 股东权益账面价值 | $54.1M | $102.7M |
| 总资产 | $94.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ASYSRGNX
| Q4 25 | $22.1M | $230.1M | ||
| Q3 25 | $17.9M | $274.2M | ||
| Q2 25 | $15.6M | $323.3M | ||
| Q1 25 | $13.4M | $267.9M | ||
| Q4 24 | $13.2M | $234.7M | ||
| Q3 24 | $11.1M | $255.5M | ||
| Q2 24 | $13.2M | $290.4M | ||
| Q1 24 | $13.0M | $338.7M |
总债务ASYSRGNX
| Q4 25 | $162.0K | — | ||
| Q3 25 | $168.0K | — | ||
| Q2 25 | $127.0K | — | ||
| Q1 25 | $135.0K | — | ||
| Q4 24 | $161.0K | — | ||
| Q3 24 | $189.0K | — | ||
| Q2 24 | $177.0K | — | ||
| Q1 24 | $65.0K | — |
股东权益ASYSRGNX
| Q4 25 | $54.1M | $102.7M | ||
| Q3 25 | $53.4M | $161.5M | ||
| Q2 25 | $51.7M | $213.7M | ||
| Q1 25 | $51.0M | $274.2M | ||
| Q4 24 | $82.4M | $259.7M | ||
| Q3 24 | $82.4M | $301.4M | ||
| Q2 24 | $81.7M | $348.3M | ||
| Q1 24 | $80.9M | $390.7M |
总资产ASYSRGNX
| Q4 25 | $94.1M | $453.0M | ||
| Q3 25 | $92.9M | $525.2M | ||
| Q2 25 | $89.5M | $581.0M | ||
| Q1 25 | $83.4M | $490.9M | ||
| Q4 24 | $117.8M | $466.0M | ||
| Q3 24 | $119.3M | $519.1M | ||
| Q2 24 | $127.1M | $569.4M | ||
| Q1 24 | $116.5M | $629.2M |
负债/权益比ASYSRGNX
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 20.2% | -174.0% |
| 资本支出强度资本支出/营收 | 1.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 37.99× | — |
| 过去12个月自由现金流最近4个季度 | $8.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ASYSRGNX
| Q4 25 | $4.1M | $-52.3M | ||
| Q3 25 | $2.3M | $-56.0M | ||
| Q2 25 | $2.5M | $-49.3M | ||
| Q1 25 | $210.0K | $33.6M | ||
| Q4 24 | $2.9M | $-31.6M | ||
| Q3 24 | $879.0K | $-40.5M | ||
| Q2 24 | $3.7M | $-45.5M | ||
| Q1 24 | $336.0K | $-55.5M |
自由现金流ASYSRGNX
| Q4 25 | $3.8M | $-52.8M | ||
| Q3 25 | $2.0M | $-56.5M | ||
| Q2 25 | $2.0M | $-49.7M | ||
| Q1 25 | $201.0K | $32.6M | ||
| Q4 24 | $2.7M | $-32.7M | ||
| Q3 24 | $447.0K | $-40.9M | ||
| Q2 24 | $322.0K | $-46.0M | ||
| Q1 24 | $-884.0K | $-56.0M |
自由现金流率ASYSRGNX
| Q4 25 | 20.2% | -174.0% | ||
| Q3 25 | 10.2% | -189.9% | ||
| Q2 25 | 10.1% | -232.8% | ||
| Q1 25 | 1.3% | 36.6% | ||
| Q4 24 | 11.2% | -154.2% | ||
| Q3 24 | 1.9% | -168.9% | ||
| Q2 24 | 1.2% | -206.2% | ||
| Q1 24 | -3.5% | -358.5% |
资本支出强度ASYSRGNX
| Q4 25 | 1.5% | 1.7% | ||
| Q3 25 | 1.2% | 1.7% | ||
| Q2 25 | 2.8% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.6% | 5.1% | ||
| Q3 24 | 1.8% | 1.3% | ||
| Q2 24 | 12.5% | 2.1% | ||
| Q1 24 | 4.8% | 3.6% |
现金转化率ASYSRGNX
| Q4 25 | 37.99× | — | ||
| Q3 25 | 2.12× | — | ||
| Q2 25 | 23.89× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 9.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 8.35× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASYS
| Thermal Processing Solutions | $14.0M | 74% |
| Semiconductor Fabrication Solutions | $5.0M | 26% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
